Диссертация (1173253), страница 21
Текст из файла (страница 21)
– 2014. – Vol. 40. – P. 1871-1876.90. Association between periodontal disease and polycystic ovary syndrome: asystematic review / S.V. Kellesarian, V.R. Malignaggi, T.V. Kellesarian [et al.] // IntJ Impot Res. – 2017. – Vol. 29, № 3. – P. 89-95.12812912991. Baldauff N.H. Polycystic ovary syndrome in adolescent girls / N.H. Baldauff, S.F.Witchel // Curr Opin Endocrinol Diabetes Obes.
– 2017. – Vol. 24, № 1. – P. 56-66.92. Bargiota A. The effects of old, new and emerging medicines on metabolicaberrations in PCOS / A. Bargiota, E. Diamani-Kandarakis // Ther. Adv. Endocrinol.Metab. – 2012. – Vol. 3, № 1. – P. 27-47.93. Bednarska S. The pathogenesis and treatment of polycystic ovary syndrome: What'snew? / S. Bednarska, A. Siejka // Adv Clin Exp Med.
– 2017. – Vol. 26, № 2. – P.359-367.94. Bhide P. Anti-Müllerian hormone and polycystic ovary syndrome / P. Bhide, R.Homburg // Best Pract Res Clin Obstet Gynaecol. – 2016. – Vol. 37. – P. 38-45.95. BrynhildsenJ.Combinedhormonalcontraceptives:prescribingpatterns,compliance, and benefits versus risks / J. Brynhildsen // Ther. Adv. Drug Saf.
–2014. – Vol. 5, № 5. – P. 201-213.96. Calprotectin is a potential prognostic marker for polycystic ovary syndrome / S.Chen, M. Jiang, T. Ding [et al.] // Ann Clin Biochem. – 2017. – Vol. 54, № 2. – P.253-257.97. Carmona-Ruiz I.O., Saucedo-de la Llata E., Moraga-Sánchez M.R. Polycystic ovarysyndrome: is there a rise in the prevalence? / I.O. Carmona-Ruiz, E. Saucedo-de laLlata, M.R.
Moraga-Sánchez [et al.] // Ginecol Obstet Mex. – 2015. – Vol. 83, № 12.– P. 750-759.98. Criteria, prevalence, and phenotypes of polycystic ovary syndrome / D. Lizneva, L.Suturina, W. Walker [et al.] // Fertil Steril. – 2016. – Vol. 106, № 1. – P. 6-15.99. Defective insulin signaling and the protective effects of dimethyldiguanide duringfollicular development in the ovaries of polycystic ovary syndrome / F.
Wang, S.Wang, Z. Zhang [et al.] // Mol Med Rep. – 2017. – Vol. 16, № 6. – P. 8164-8170.100.Differential Expression of microRNAs in the Ovaries from Letrozole-InducedRat Model of Polycystic Ovary Syndrome / D. Li, C. Li, Y. Xu [et al.] // DNA CellBiol. – 2016. – Vol. 35, № 4. – P.
177-183.129130130101.Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism andimplication for pathogenesis / A. Dunaif // Endocrinol. Rev. – 1997. – Vol. 6. – P.774-800.102.Duncan W.C. A guide to understanding polycystic ovary syndrome (PCOS) /W.C.
Duncan // J Fam Plann Reprod Health Care. – 2014. – Vol. 40, № 3. – P. 217225.103.Epidemiology, diagnosis and managemen of hirsutism: a consensus statemet bythe Androgen Excess and Polycystic Ovary Syndrome Society / H.F. EscobarMorreale, E. Carmina, D. Dewailly [et al.] // Hum. Reprod. Update. – 2012. – Vol.18, № 2. – P.146-170.104.European Progestin Club Guidelines for prevention and treatment of threatenedor recurrent (habitual) miscarriage with progestogens / A.E. Schindler, H. Carp, R.Druckmann [et al.] // Gynecol. Endocrinol. – 2015. Vol.
15. – P. 1-3.105.Farquhar C. Laparoscopic drilling by diathermy or laser for ovulation inductionin anovulatory polycystic ovary syndrome / C. Farquhar, J. Brown, J. Marjoribanks //Cochrane Database Syst. Rev. – 2012. – Vol. 6. – CD001122.106.Features of Polycystic Ovary Syndrome in adolescence / P. Tsikouras, L. Spyros,B. Manav [et al.] // J Med Life. – 2015. – Vol. 8, № 3. – P. 291-296.107.Functional Characterization of MicroRNA-27a-3p Expression in HumanPolycystic Ovary Syndrome / M. Wang, J. Sun, B.
Xu [et al.] // Endocrinology. –2018. – Vol. 159, № 1. – P. 297-309.108.Glintborg D. Endocrine and metabolic characteristics in polycystic ovarysyndrome / D. Glintborg // Dan Med J. – 2016. – Vol. 63, № 4. – P. 32.109. Glintborg D. Management of endocrine disease: Morbidity in polycystic ovarysyndrome / D. Glintborg, M. Andersen // Eur J Endocrinol.
– 2017. – Vol. 176, № 2.– P. 53-65.110. Glintborg D. Medical comorbidity in polycystic ovary syndrome with specialfocus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updatedreview / D. Glintborg, M. Andersen // Curr Opin Obstet Gynecol.
– 2017. – Vol. 29,№ 6. – P. 390-396.130131131111. History of discovery of polycystic ovary syndrome / Adv Clin Exp Med. – 2017.– Vol. 26, № 3. – P. 555-558.112. Identification of microRNAs and genes associated with hyperandrogenism in thefollicular fluid of women with polycystic ovary syndrome / Y. Xue, J. Lv, P.
Xu [etal.] // J Cell Biochem. – 2018. – Vol. 119, № 5. – P. 3913-3921.113. Ilie I.R. Polycystic Ovary Syndrome-Epigenetic Mechanisms and AberrantMicroRNA / I.R. Ilie, C.E. Georgescu // Adv Clin Chem. – 2015. – Vol. 71. – P. 2545.114. Insulin and the polycystic ovary syndrome / D. Macut, J. Bjekić-Macut, D.Rahelić [et al.] // Diabetes Res Clin Pract. – 2017. – Vol.
130. – P. 163-170.115. Łebkowska A. Anti-Müllerian hormone and polycystic ovary syndrome / A.Łebkowska, I. Kowalska // Endokrynol Pol. – 2017. – Vol. 68, № 1. – P. 74-78.116. Livadas S. Polycystic ovary syndrome: dedinutions, phenotypes and diagnosticapproach / S. Livadas, E. Diamanti-Kandarakis // Front. Horm. Res. – 2013. – Vol.40. – P. 1-21.117. McCartney C.R.
Clinical practice. Polycystic Ovary Syndrome / C.R. McCartney,J.C. Marshall // N Engl J Med. – 2016. – Vol. 375, № 1. – P. 54-64.118. Metformin: an old medication of new fashion: evolving new molecularmechanisms and clinical implications in polycystic ovary syndrome / Diamani- E.Kandarakis, C.D. Christakou, E. Kandaraki [et al.] // Eur. J. Endocrinol. Eur. Fed.Endocr. Soc. – 2010. – Vol.
162, № 2. – P. 193-212.119. Moghetti P. Insulin Resistance and Polycystic Ovary Syndrome / P. Moghetti //Curr Pharm Des. – 2016. – Vol. 22, № 36. – P. 5526-5534.120. Moore A.M. Polycystic ovary syndrome: Understanding the role of the brain /A.M. Moore, R.E. Campbell // Front Neuroendocrinol. – 2017. – Vol. 46. – P.
1-14.121. Neuroendocrine androgen action is a key extraovarian mediator in thedevelopment of polycystic ovary syndrome / A.S.L. Caldwell, M.C. Edwards, R.Desai [et al.] // Proc Natl Acad Sci USA. – 2017. – Vol. 114, № 16. – P. 34-43.122. Obesity and polycystic ovary syndrome / N.
Naderpoor, S. Shorakae, A. Joham[et al.] // Minerva Endocrinol. – 2015. – Vol. 40, № 1. – P. 37-51.131132132123. Polycystic Ovarian Syndrome: Long-Term Health Consequences / T. Zore, N.V.Joshi, D. Lizneva [et al.] // Semin Reprod Med. – 2017. – Vol. 35, № 3. – P. 271281.124. Polycystic ovary syndrome is associated with anogenital distance, a marker ofprenatal androgen exposure / Y. Wu, G. Zhong, S. Chen [et al.] // Hum Reprod. –2017. – Vol. 32, № 4. – P. 937-943.125. Polycystic ovary syndrome, personality, and depression: A twin study / C.E.Cesta, R.
Kuja-Halkola, K. Lehto [et al.] // Psychoneuroendocrinology. – 2017. –Vol. 85. – P. 63-68.126. Pregnancy outcomes and the effect of metformin treatment in women withpolycystic ovary syndrome: an overview / G.S. Ghazeeri, A.H. Nassar, Z. Younes [etal.] // Acta Obstet. Gynecol. Scand. – 2012.
– Vol. 96, № 6. – P. 658-678.127. Protective effects of GABA against metabolic and reproductive disturbances inletrozole induced polycystic ovarian syndrome in rats / A. Ullah, S. Jahan, S. Razak[et al.] // J Ovarian Res. – 2017. – Vol. 10, № 1. – P. 62.128. Quantitative assessment of nutrition in patients with polycystic ovary syndrome(PCOS) / M. Szczuko, M.
Skowronek, M. Zapałowska-Chwyć [et al.] // RoczPanstw Zakl Hig. – 2016. – Vol. 67, № 4. – P. 419-426.129. Rutkowska A.Z. Polycystic ovary syndrome and environmental toxins / A.Z.Rutkowska, E. Diamanti-Kandarakis // Fertil Steril. – 2016. – Vol. 106, № 4. – P.948-58.130. Setji T.L. Polycystic ovary syndrome: update on diagnosis and treatment / T.L.Setji, A.J.
Brown // Am J Med. – 2014. – Vol. 127, № 10. – P. 912-919.131. Seyam E. Evaluation of the correlation between insulin like factor 3, polycysticovary syndrome, and ovarian maldescent / E. Seyam, E. Hefzy // GynecolEndocrinol. – 2018. – Vol. 34, № 6. – P. 481-488.132. Shah D. Polycystic ovaries - beyond menopause. / D. Shah, S. Bansal //Climacteric. – 2014. – Vol.
17, № 2. – P. 109-15.133. Shah D. Polycystic ovary syndrome and metabolic syndrome: the worrisometwosome? / D. Shah, S. Rasool // Climacteric. – 2016. – Vol. 19, № 1. – P. 7-16.132133133134. Tziomalos K. Cardiovascular Risk in the Different Phenotypes of PolycysticOvary Syndrome / K. Tziomalos // Curr Pharm Des. – 2016. – Vol. 22, № 36.
– P.5547-5553.135. Yong E.L. Polycystic Ovarian Syndrome - Issue 30.8 / E.L. Yong // Best PractRes Clin Obstet Gynaecol. – 2016. – Vol. 37. – P. 1-4.133.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
